Corynebacterium sp. bacteria and minicell derived therefrom, and use thereof

Patent metadata

Field	Value
Publication number	US-10130712-B2
Application number	US-201515023245-A
Country	US
Kind code	B2
Filing date	Oct 21, 2015
Priority date	Mar 4, 2015
Publication date	Nov 20, 2018
Grant date	Nov 20, 2018

Abstract

A drug delivery system composition includes Corynebacterium sp. bacteria or Corynebacterium sp. bacteria-derived minicells. The drug delivery system composition is safer for use in human bodies than other bacteria (for example, Escherichia coli ( E. coli ), Salmonella sp. bacteria, Bacillus sp. bacteria, or the like), or other bacteria-derived drug delivery system. When an anti-cancer drug protein expression construct (protein expression recombinant vector or the like) is included, over-expression of an anti-cancer drug protein, effective protein expression control in vivo, and targeting technique using expression of targeting factor. The drug delivery system composition enables stable drug delivery in vivo, thereby maximizing anti-cancer therapeutic effects.

First claim

The invention claimed is:

1. A drug delivery system composition, comprising a drug; and a minicell carrying the drug, wherein the minicell is derived from a parA gene-depleted mutant strain of Corynebacterium sp. bacteria or a NCgl1366 gene-depleted mutant strain of Corynebacterium sp. bacteria, and the Corynebacterium sp. bacteria is selected from the group consisting of Corynebacterium glutamicum, Corynebacterium ammoniagenes, Corynebacterium casei, Corynebacterium efficiens , and a combination thereof.

2. The drug delivery system composition of claim 1 , wherein the drug is an anti-cancer agent.

3. The drug delivery system composition of claim 2 , wherein the anti-cancer agent is to inhibit or cure at least one cancer selected from the group consisting of breast cancer, cervical cancer, ovarian cancer, endometrial cancer, melanoma, bladder cancer, lung cancer, pancreatic cancer, colon cancer, prostate cancer, leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, B-cell lymphoma, acute myelogenous leukemia (AML), chronic myelogenous leukemia, thyroid cancer, thyroid follicular cancer, kidney cancer, spleen cancer, craniocervical disorder, gastric cancer, liver cancer, bone cancer, brain cancer, cholangiocarcinoma, small bowel cancer, uterine cancer, and testicular cancer.

4. The drug delivery system composition of claim 2 , wherein the anti-cancer agent is at least one anti-cancer agent selected from the group consisting of a chemical preparation, a protein, and a nucleic acid.

5. The drug delivery system composition of claim 4 , wherein the anti-cancer agent is the chemical preparation selected from the group consisting of doxorubicin, paclitaxel, docetaxel, cisplatin, carboplatin, oxaliplatin, daunorubicin, epirubicin, idarubicin, valubicin, mitoxantrone, curcumin, gefitinib, erlotinib, irinotecan, topotecan, vinblastine, and vincristine.

6. The drug delivery system composition of claim 4 , wherein the anti-cancer agent is the protein selected from the group consisting of an antibody, a transport protein, a structural protein, a regulatory protein, a hormone, a hormone analogue, a cytokine-derived anti-cancer protein, a cytolysis protein, an amino acid lyase, an antiangiogenic factor, a cell adhesion molecule, an enzyme inhibitor, a receptor, a fragment of a receptor, and immunotoxin.

7. The drug delivery system composition of claim 6 , wherein the protein is the antibody selected from the group consisting of an immunoglobulin, an antibody fragment, and an antibody analogue.

8. The drug delivery system composition of claim 7 , wherein the antibody is the antibody fragment selected from the group consisting of Fab, Fab', F(ab')2, F(ab'), F(ab), Fv, and scFv.

9. The drug delivery system composition of claim 7 , wherein the antibody is the antibody analogue selected from the group consisting of affibody, repebody, affilin, DARPin, tetranectin, microbody, peptide aptamer, and avimer.

10. The drug delivery system composition of claim 4 , wherein the anti-cancer agent is the nucleic acid selected from the group consisting of siRNA, shRNA, miRNA, antisense RNA, lincRNA, ribozyme, and peptide nucleic acids (PNA).

11. The drug delivery system composition of claim 1 , wherein the drug delivery system composition comprises a construct that expresses a protein.

12. The drug delivery system composition of claim 11 , wherein the protein comprises (1) an anti-cancer protein, (2) an anti-cancer protein and a cancer cell surface receptor, or (3) an anti-cancer protein and a cancer cell surface antigen.

13. The drug delivery system composition of claim 11 , wherein the construct comprises a polynucleotide sequence that encodes a protein linker.

14. The drug delivery system composition of claim 11 , wherein the construct comprises a polynucleotide sequence that encodes a ramp tag.

15. An anti-cancer pharmaceutical composition comprising, the drug delivery system composition of claim 1 , wherein the drug is a pharmaceutically effective amount of an anti-cancer agent as an active ingredient.

16. The drug delivery system composition of claim 4 , wherein the anti-cancer agent comprises an anti-cancer protein and at least one of a cancer cell surface receptor and a cancer cell surface antigen.

Assignees

• Univ Nat Chonnam Ind Found

Inventors

• Kim Geun Joong
• Lee Jin-Young
• Min Sa-Young
• You Sung-Hwan
• Min Jung-Joon

Classifications

• A61K47/6901

  Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors · CPC title

• Y02A50/473

  Cross-Sectional Technologies · mapped topic

• C12Y305/01001

  Asparaginase (3.5.1.1) · CPC title

• A61K38/50

  acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase · CPC title

• A61K47/46 Primary

  Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts · CPC title